Drugs / AZD3759
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07620951 | Jul → Aug 2026 overdue | central nervous system cancer, lung cancer | Alpha Biopharma (Jiangsu) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07361705 | Jan 2026 → Apr 2028 expected | — | Alpha Biopharma (Jiangsu) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT02228369 | Nov 2014 → Aug 2017 | lung cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03360929 | Oct 2017 → Nov 2020 | non-small cell lung carcinoma | LYZZ Alpha Holding Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07551414 | May 2026 → May 2027 expected | neoplastic meningitis, non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03574402 | Jul 2018 → Dec 2022 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03653546 | Oct 2018 → Jul 2022 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Alpha Biopharma (Jiangsu) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3759 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03653546 ↗ |
| Known as | [14C]Zorifertinib | “This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety...” NCT07620951 ↗ |
| Known as | zorifertinib | “Zorifertinib (AZD3759), an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with high blood-brain barrier penetration capability, demonstrated promising...” PMID 39389055 ↗ Oct 20244“Zorifertinib (AZD3759), an EGFR-tyrosine kinase inhibitor (TKI) with high blood-brain barrier penetration” PMID 38666433 ↗ Apr 2024 |
| Action | Inhibit | “AZD3759 is a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the blood-brain barrier.” PMID 29056570 ↗ Oct 2017 |
| Modality | Small molecule | “an EGFR-tyrosine kinase inhibitor (TKI)” PMID 38666433 ↗ Apr 2024 |
| Route | Oral | “Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291” NCT02228369 ↗ |
| Target | EGFR | “AZD3759 is a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the blood-brain barrier.” PMID 29056570 ↗ Oct 2017 |